Industry Perspectives

Sartorius launches Cubis® III balances with built-in compliance and connectivity

Cubis® III integrates compliance, secure connectivity, and guided weighing workflows directly on the instrument, reducing reliance on middleware and simplifying validation in regulated lab environments.
Written bySartorius
| 2 min read
The Cubis III lab balance.

credit: Sartorius

Register for free to listen to this article
Listen with Speechify
0:00
2:00

Göttingen, Germany — June 3, 2026 — Sartorius has launched Cubis® III, the latest innovation in its premium line of lab balances, delivering compliant, connected weighing without relying on extra software typically required to bridge instruments and lab systems. With built-in connectivity, native compliance features, and configurable on-instrument workflows, Cubis III integrates directly into any digital ecosystem, simplifying validation, IT effort, and long-term maintenance.

“For compliance-driven labs, a balance is a critical data source. But in many setups, meeting regulations depends on an additional middleware layer,” said Eszter Paldy, Manager of Product Management Premium Weighing Solutions at Sartorius. “With Cubis III, compliance and connectivity are handled on the instrument, so labs can choose how they want to integrate and connect directly from the device.”

Cubis III delivers direct, standards-based connectivity so weighing data can flow securely into existing informatics environments. An embedded OPC UA server and support for enterprise protocols such as HTTPS, FTPS, and SMB enable direct integration into LIMS, ELN, and CDS without custom, point-to-point solutions. Role-based access control and LDAP integration bring enterprise IT practices to the device, supporting secure user management across balance fleets.

Compliance features are fully embedded in the instrument. On-instrument audit trails and electronic signatures support 21 CFR Part 11 requirements, along with guided, pharmacopeia-aligned weighing workflows that enforce consistency across sites and users. Digitized cleaning workflows (Cleaning QApp) capture cleanings with authenticated sign-off, improving documentation and traceability without additional paperwork.

By removing the dependency on standalone middleware, Cubis III reduces the scope of systems that must be installed, qualified, and maintained, streamlining lifecycle management and making it easier to scale balance fleets over time. High accuracy with small sample quantities also supports efficient use of valuable materials.

With two packages, Cubis III and Cubis III Max, Sartorius enables labs to choose the level of data handling and workflow sophistication that best fits their needs today, while retaining the flexibility to expand capabilities over time through additional workflows and integrations. For labs facing growing demands around compliance, data governance and cost control, Cubis III lab balances provide a scalable foundation for a more connected, efficient and future-ready lab.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
3D illustration of a protein complex composed of clustered spherical subunits arranged in a ring-like oligomeric structure, shown in shades of blue, cyan, and purple against a blue gradient background.
Automated mass photometry helps reveal the complex dynamics of protein oligomerization and the factors that govern protein assembly.
Illustration of translucent Y-shaped antibodies floating in a soft blue and green background, representing antibody research, development, and biomedical science.
Explore how antibody accessibility and custom development strategies can influence the pace and success of translational research.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue